Yahoo
NYSE - Nasdaq Real Time Price USD

Haemonetics Corporation (HAE)

119.82 +0.03 (+0.02%)
As of 11:10:04 AM EDT. Market Open.
Trade HAE on Coinbase
Chart Range Bar
Loading chart for HAE
  • Previous Close 119.79
  • Open 120.50
  • Bid 119.08 x 20000
  • Ask 119.93 x 20000
  • Day's Range 119.15 - 120.47
  • 52 Week Range 49.00 - 123.77
  • Volume 37,145
  • Avg. Volume 730,903
  • Market Cap (intraday) 5.451B
  • Beta (5Y Monthly) 0.61
  • PE Ratio (TTM) 57.79
  • EPS (TTM) 2.07
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 124.50
  • Zacks Rating Bullish

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

www.haemonetics.com

3,009

Full Time Employees

March 28

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HAE
49.26%
S&P 500 (^GSPC)
11.27%

1-Year Return

HAE
139.32%
S&P 500 (^GSPC)
11.65%

3-Year Return

HAE
40.88%
S&P 500 (^GSPC)
82.80%

5-Year Return

HAE
74.12%
S&P 500 (^GSPC)
65.40%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 339.38M
Earnings 33.01M
Profit Margin 9.73%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
100M
200M
300M
-5.0%
0.0%
5.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

86.00 Low
124.50 Average
119.82 Current
142.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/9/2026
Analyst Barrington Research
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 118 -> 140

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.12%

  • Return on Assets (ttm)

    6.60%

  • Return on Equity (ttm)

    11.20%

  • Revenue (ttm)

    1.35B

  • Net Income Avi to Common (ttm)

    96.29M

  • Diluted EPS (ttm)

    2.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    224.52M

  • Total Debt/Equity (mrq)

    140.26%

  • Levered Free Cash Flow (ttm)

    312.84M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: